NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback